temozolomide

Phase 3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Brain and Central Nervous System Tumors

Conditions

Brain and Central Nervous System Tumors

Trial Timeline

Dec 1, 2007 → Dec 1, 2029

NCT ID

NCT00626990

About temozolomide

temozolomide is a phase 3 stage product being developed by Merck for Brain and Central Nervous System Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT00626990. Target conditions include Brain and Central Nervous System Tumors.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01127594	Phase 1	Completed	Jul 1, 2010	Jun 1, 2014	Melanoma
NCT00638963	Phase 2	Terminated	Oct 2, 2008	Jun 30, 2010	Breast Neoplasm
NCT00686725	Approved	Completed	Jun 24, 2008	Sep 28, 2011	Glioblastoma
NCT00632203	Phase 2	Terminated	Mar 4, 2008	Jan 7, 2011	Carcinoma, Non-Small-Cell Lung
NCT00723827	Pre-clinical	Completed	Mar 1, 2008	Sep 1, 2011	Glioblastoma
NCT00626990	Phase 3	Active	Dec 1, 2007	Dec 1, 2029	Brain and Central Nervous System Tumors
NCT00687323	Phase 2	Completed	Jul 30, 2007	Dec 23, 2012	Leukemia, Acute Myeloid
NCT00725010	Pre-clinical	Completed	Apr 1, 2007	Apr 1, 2009	Glioblastoma
NCT00423150	Phase 2	Terminated	Jan 26, 2007	Jun 11, 2009	Colorectal Neoplasm
NCT00424554	Phase 2	Completed	Sep 26, 2006	Feb 16, 2011	Glioma
NCT00392171	Phase 2	Completed	Jun 9, 2006	Sep 15, 2009	Glioma
NCT00704808	Pre-clinical	Completed	May 1, 2006	Dec 1, 2008	Glioblastoma
NCT00684567	Phase 2	Completed	Sep 27, 2005	Oct 31, 2007	Glioblastoma
NCT00076856	Phase 2	Completed	Mar 31, 2004	Mar 31, 2006	Carcinoma, Non-Small-Cell Lung
NCT00783393	Phase 2	Completed	May 27, 2003	Jun 17, 2005	Astrocytoma
NCT00034697	Phase 2	Terminated	Jun 28, 2001	Jan 30, 2003	Metastases, Neoplasm
NCT00831545	Phase 2	Completed	Dec 1, 2000	Oct 20, 2006	Metastases of Central Nervous System

Competing Products

20 competing products in Brain and Central Nervous System Tumors

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Endocrine therapy	Eli Lilly	Phase 1/2	41
Duloxetine + Sugar pill	Eli Lilly	Phase 2	52
Neurosteroid enantiomer	Oragenics	Phase 2	44
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	52
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	33
Eribulin Mesylate	Eisai	Phase 1	33
Pembrolizumab + Lenvatinib	Eisai	Phase 2	52
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	52
GLIADEL	Eisai	Phase 2	52
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	33
abemaciclib + abemaciclib	Eli Lilly	Phase 2	52
JNJ-17299425	Johnson & Johnson	Phase 2	52
ABT-888	AbbVie	Phase 1	33
Veliparib + Placebo	AbbVie	Phase 2	52
Iressa (Gefitinib)	AstraZeneca	Phase 2	52
Trastuzumab deruxtecan	AstraZeneca	Phase 2	52
Exenatide	AstraZeneca	Approved	85
AZD5213	AstraZeneca	Phase 1	33

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved